Invest in the Future of Regenerative Medicine
Welcome to Investor Relations. Here, you will find the latest information on BIONCaRT GmbH’s corporate strategy, clinical development progress, market entry plans, funding rounds, and investment opportunities.
BIONCaRT at a Glance
Our Focus
BIONCaRT specializes in the development, approval, and manufacturing of allogeneic, stem cell-based medicines for the treatment of orthopedic diseases.
Our focus is on innovative therapeutic concepts for the regeneration of articular cartilage, based on mesenchymal stromal cells (MSCs) derived from umbilical cord tissue.
About MesemCart
MesemCart is a cell therapy for the treatment of focal cartilage defects in the knee joint. The processed MSCs are applied to a collagen-based matrix and implanted minimally invasively.
MesemCart offers a promising alternative to autologous therapies – without the need for a second surgery, with standardized cell quality, and rapid availability.
Milestones
- 2017: Founding of Bioplanta GmbH
- 2020: Successful Preclinical Safety Testing in the Mouse Model
- 2024: Renaming to BIONCaRT GmbH
- 2025: Start of the Clinical Trial
- 2027: Planned Market Entry in Germany
- 2030: Planned European Market Approval
- 2032: Planned Approval by the FDA
Clinical Study
MesemCart is currently being tested for safety and initial efficacy in the treatment of cartilage defects in a regulatory-approved Phase I/IIa study.
Strategic Markets & Expansion Potential
The need for innovative treatment solutions for cartilage defects is continuously increasing. Current epidemiological data show that several million people worldwide are affected by cartilage damage each year – many of them in the knee joint.
At the same time, there are still only limited approved regenerative treatment options available.
MesemCart specifically addresses this growing medical need with an innovative, allogeneic-based therapeutic approach.
Primary Markets
Germany: Focus on Market Introduction and Initial Regulatory Strategy
European Union: EMA Approval Expansion and Market Growth
USA: FDA Approval Expansion and Market Growth
Forecasts suggest that the global market for regenerative joint tissue will experience double-digit annual growth in the coming years – driven by demographic trends, increased health awareness, and the growing demand for minimally invasive treatment options.
BIONCaRT is positioning itself early in an attractive and rapidly growing market segment with significant medical and economic need.
Market Figures
Patient Need
Damage to the hyaline articular cartilage is found in approximately 60–80% of all knee arthroscopies.
Cell Therapy Growth
The projected annual market growth for cell therapy is estimated at 17% to 25% CAGR (Compound Annual Growth Rate) through 2030.
Cartilage Therapy Segment
The global market size for stem cell-based cartilage regeneration is expected to reach approximately USD 0.45 billion by 2032.
Unmet Medical Need
Few approved allogeneic stem cell cartilage therapies exist — giving MesemCart a first-mover advantage.
Clinical Trial and Next Steps
MesemCart is currently being evaluated in a prospective, multicenter Phase I/IIa clinical trial. This study aims to assess the safety, tolerability, and initial signs of efficacy of the therapy in patients with focal cartilage defects of the knee joint.
01
Key Data
Study Type: Prospective, Multicenter, non randomised
Primary Endpoints: Safety (Incidence of Adverse Events), Tolerability
Status: Patient Recruitment Not Yet Started
02
Long-Term Perspective
With the successful completion of the clinical trial and approval process, BIONCaRT aims to commercialize MesemCart initially in the German market, followed by a Europe-wide expansion and a subsequent market launch in the USA.
Meet Us
BIONCaRT regularly participates in industry conferences, investor events, and sector-specific gatherings. Here, you can find upcoming dates and opportunities to engage with us.
This is news
Invest in the Future of an Emerging Industry
With MesemCart, BIONCaRT is positioning itself in a dynamically growing market with high medical need. Benefit from the early stage of our clinical development and join us on the path to market approval.
